Summary
Global Markets Direct’s, ‘Renal Cell Carcinoma - Pipeline Review, H1 2016’, provides an overview of the Renal Cell Carcinoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Renal Cell Carcinoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma
- The report reviews pipeline therapeutics for Renal Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Renal Cell Carcinoma therapeutics and enlists all their major and minor projects
- The report assesses Renal Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Renal Cell Carcinoma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Renal Cell Carcinoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc.
Acceleron Pharma, Inc.
Advenchen Laboratories, LLC
Altor BioScience Corporation
Ambrx, Inc.
Amgen Inc.
Ampio Pharmaceuticals, Inc.
arGEN-X BV
Argos Therapeutics, Inc.
Arrowhead Pharmaceuticals, Inc.
Astellas Pharma Inc.
Bayer AG
Beta Pharma, Inc.
Bio-Cancer Treatment International Limited
BIOCAD
Bionomics Limited
Bionovis SA
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Caladrius Biosciences, Inc.
Calithera Biosciences, Inc.
Cellceutix Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Cerulean Pharma, Inc.
Chipscreen Biosciences Ltd
Cytune Pharma SAS
Dr. Reddy's Laboratories Limited
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Genor BioPharma Co., Ltd.
GenSpera, Inc.
GlaxoSmithKline Plc
Horizon Pharma Plc
Hutchison MediPharma Limited
Immatics Biotechnologies GmbH
Immune Design Corp.
Immunicum AB
ImmunoGen, Inc.
Incuron, LLC
Incyte Corporation
KAHR medical Ltd.
Karyopharm Therapeutics, Inc.
KineMed, Inc.
Kyowa Hakko Kirin Co., Ltd.
Lead Discovery Center GmbH
Mabion SA
MacroGenics, Inc.
MediaPharma s.r.l.
MedImmune, LLC
Medivation, Inc.
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Mirna Therapeutics, Inc.
Molecular Partners AG
Mologen AG
Monopar Therapeutics LLC
Mycenax Biotech Inc.
Nektar Therapeutics
NewLink Genetics Corporation
Novartis AG
NovaTarg Therapeutics, Inc
Omeros Corporation
Oncobiologics, Inc.
OncoMax
Ono Pharmaceutical Co., Ltd.
Panacea Biotec Limited
Peloton Therapeutics, Inc.
Pfizer Inc.
Prima BioMed Ltd.
PsiOxus Therapeutics Limited
Rexahn Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Sevion Therapeutics, Inc.
Sillajen Biotherapeutics
Sorrento Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Syndax Pharmaceuticals, Inc.
Taiwan Liposome Company, Ltd.
TC BioPharm Limited
Theravectys SA
Threshold Pharmaceuticals, Inc.
Tocagen Inc.
TRACON Pharmaceuticals, Inc.
TVAX Biomedical, Inc.
Tyrogenex, Inc.
Vascular Biogenics Ltd.
ViiV Healthcare Limited
X4 Pharmaceuticals, Inc.
'
Table of Contents
Table of Contents 2
Introduction 7
Renal Cell Carcinoma Overview 8
Therapeutics Development 9
Renal Cell Carcinoma - Therapeutics under Development by Companies 11
Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 19
Renal Cell Carcinoma - Pipeline Products Glance 20
Renal Cell Carcinoma - Products under Development by Companies 24
Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 34
Renal Cell Carcinoma - Companies Involved in Therapeutics Development 35
Renal Cell Carcinoma - Therapeutics Assessment 129
Drug Profiles 157
Renal Cell Carcinoma - Recent Pipeline Updates 479
Renal Cell Carcinoma - Dormant Projects 765
Renal Cell Carcinoma - Discontinued Products 779
Renal Cell Carcinoma - Product Development Milestones 783
Appendix 794
List of Tables
Number of Products under Development for Renal Cell Carcinoma, H1 2016 25
Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H1 2016 26
Number of Products under Development by Companies, H1 2016 28
Number of Products under Development by Companies, H1 2016 (Contd..1) 29
Number of Products under Development by Companies, H1 2016 (Contd..2) 30
Number of Products under Development by Companies, H1 2016 (Contd..3) 31
Number of Products under Development by Companies, H1 2016 (Contd..4) 32
Number of Products under Development by Companies, H1 2016 (Contd..5) 33
Number of Products under Development by Companies, H1 2016 (Contd..6) 34
Number of Products under Investigation by Universities/Institutes, H1 2016 35
Comparative Analysis by Late Stage Development, H1 2016 36
Comparative Analysis by Clinical Stage Development, H1 2016 37
Comparative Analysis by Early Stage Development, H1 2016 38
Comparative Analysis by Unknown Stage Development, H1 2016 39
Products under Development by Companies, H1 2016 40
Products under Development by Companies, H1 2016 (Contd..1) 41
Products under Development by Companies, H1 2016 (Contd..2) 42
Products under Development by Companies, H1 2016 (Contd..3) 43
Products under Development by Companies, H1 2016 (Contd..4) 44
Products under Development by Companies, H1 2016 (Contd..5) 45
Products under Development by Companies, H1 2016 (Contd..6) 46
Products under Development by Companies, H1 2016 (Contd..7) 47
Products under Development by Companies, H1 2016 (Contd..8) 48
Products under Development by Companies, H1 2016 (Contd..9) 49
Products under Investigation by Universities/Institutes, H1 2016 50
Renal Cell Carcinoma - Pipeline by AbbVie Inc., H1 2016 51
Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H1 2016 52
Renal Cell Carcinoma - Pipeline by Advenchen Laboratories, LLC, H1 2016 53
Renal Cell Carcinoma - Pipeline by Altor BioScience Corporation, H1 2016 54
Renal Cell Carcinoma - Pipeline by Ambrx, Inc., H1 2016 55
Renal Cell Carcinoma - Pipeline by Amgen Inc., H1 2016 56
Renal Cell Carcinoma - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 57
Renal Cell Carcinoma - Pipeline by arGEN-X BV, H1 2016 58
Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H1 2016 59
Renal Cell Carcinoma - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016 60
Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H1 2016 61
Renal Cell Carcinoma - Pipeline by Bayer AG, H1 2016 62
Renal Cell Carcinoma - Pipeline by Beta Pharma, Inc., H1 2016 63
Renal Cell Carcinoma - Pipeline by Bio-Cancer Treatment International Limited, H1 2016 64
Renal Cell Carcinoma - Pipeline by BIOCAD, H1 2016 65
Renal Cell Carcinoma - Pipeline by Bionomics Limited, H1 2016 66
Renal Cell Carcinoma - Pipeline by Bionovis SA, H1 2016 67
Renal Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 68
Renal Cell Carcinoma - Pipeline by Boston Biomedical, Inc., H1 2016 69
Renal Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 70
Renal Cell Carcinoma - Pipeline by Caladrius Biosciences, Inc. , H1 2016 71
Renal Cell Carcinoma - Pipeline by Calithera Biosciences, Inc., H1 2016 72
Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H1 2016 73
Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 74
Renal Cell Carcinoma - Pipeline by Celltrion, Inc., H1 2016 75
Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H1 2016 76
Renal Cell Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H1 2016 77
Renal Cell Carcinoma - Pipeline by Cytune Pharma SAS, H1 2016 78
Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 79
Renal Cell Carcinoma - Pipeline by EirGenix Inc., H1 2016 80
Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H1 2016 81
Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H1 2016 82
Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H1 2016 83
Renal Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 84
Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H1 2016 85
Renal Cell Carcinoma - Pipeline by GenSpera, Inc., H1 2016 86
Renal Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H1 2016 87
Renal Cell Carcinoma - Pipeline by Horizon Pharma Plc, H1 2016 88
Renal Cell Carcinoma - Pipeline by Hutchison MediPharma Limited, H1 2016 89
Renal Cell Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H1 2016 90
Renal Cell Carcinoma - Pipeline by Immune Design Corp., H1 2016 91
Renal Cell Carcinoma - Pipeline by Immunicum AB, H1 2016 92
Renal Cell Carcinoma - Pipeline by ImmunoGen, Inc., H1 2016 93
Renal Cell Carcinoma - Pipeline by Incuron, LLC, H1 2016 94
Renal Cell Carcinoma - Pipeline by Incyte Corporation, H1 2016 95
Renal Cell Carcinoma - Pipeline by KAHR medical Ltd., H1 2016 96
Renal Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 97
Renal Cell Carcinoma - Pipeline by KineMed, Inc., H1 2016 98
Renal Cell Carcinoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 99
Renal Cell Carcinoma - Pipeline by Lead Discovery Center GmbH, H1 2016 100
Renal Cell Carcinoma - Pipeline by Mabion SA, H1 2016 101
Renal Cell Carcinoma - Pipeline by MacroGenics, Inc., H1 2016 102
Renal Cell Carcinoma - Pipeline by MediaPharma s.r.l., H1 2016 103
Renal Cell Carcinoma - Pipeline by MedImmune, LLC, H1 2016 104
Renal Cell Carcinoma - Pipeline by Medivation, Inc., H1 2016 105
Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H1 2016 106
Renal Cell Carcinoma - Pipeline by Merck KGaA, H1 2016 107
Renal Cell Carcinoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 108
Renal Cell Carcinoma - Pipeline by Mirna Therapeutics, Inc., H1 2016 109
Renal Cell Carcinoma - Pipeline by Molecular Partners AG, H1 2016 110
Renal Cell Carcinoma - Pipeline by Mologen AG, H1 2016 111
Renal Cell Carcinoma - Pipeline by Monopar Therapeutics LLC, H1 2016 112
Renal Cell Carcinoma - Pipeline by Mycenax Biotech Inc., H1 2016 113
Renal Cell Carcinoma - Pipeline by Nektar Therapeutics, H1 2016 114
Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H1 2016 115
Renal Cell Carcinoma - Pipeline by Novartis AG, H1 2016 116
Renal Cell Carcinoma - Pipeline by NovaTarg Therapeutics, Inc, H1 2016 117
Renal Cell Carcinoma - Pipeline by Omeros Corporation, H1 2016 118
Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H1 2016 119
Renal Cell Carcinoma - Pipeline by OncoMax, H1 2016 120
Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 121
Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H1 2016 122
Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H1 2016 123
Renal Cell Carcinoma - Pipeline by Pfizer Inc., H1 2016 124
Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H1 2016 125
Renal Cell Carcinoma - Pipeline by PsiOxus Therapeutics Limited, H1 2016 126
Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016 127
Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H1 2016 128
Renal Cell Carcinoma - Pipeline by Sevion Therapeutics, Inc., H1 2016 129
Renal Cell Carcinoma - Pipeline by Sillajen Biotherapeutics, H1 2016 130
Renal Cell Carcinoma - Pipeline by Sorrento Therapeutics, Inc., H1 2016 131
Renal Cell Carcinoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 132
Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016 133
Renal Cell Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 134
Renal Cell Carcinoma - Pipeline by TC BioPharm Limited, H1 2016 135
Renal Cell Carcinoma - Pipeline by Theravectys SA, H1 2016 136
Renal Cell Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 137
Renal Cell Carcinoma - Pipeline by Tocagen Inc., H1 2016 138
Renal Cell Carcinoma - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016 139
Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H1 2016 140
Renal Cell Carcinoma - Pipeline by Tyrogenex, Inc., H1 2016 141
Renal Cell Carcinoma - Pipeline by Vascular Biogenics Ltd., H1 2016 142
Renal Cell Carcinoma - Pipeline by ViiV Healthcare Limited, H1 2016 143
Renal Cell Carcinoma - Pipeline by X4 Pharmaceuticals, Inc., H1 2016 144
Assessment by Monotherapy Products, H1 2016 145
Assessment by Combination Products, H1 2016 146
Number of Products by Stage and Target, H1 2016 148
Number of Products by Stage and Mechanism of Action, H1 2016 161
Number of Products by Stage and Route of Administration, H1 2016 170
Number of Products by Stage and Molecule Type, H1 2016 172
Renal Cell Carcinoma Therapeutics - Recent Pipeline Updates, H1 2016 495
Renal Cell Carcinoma - Dormant Projects, H1 2016 781
Renal Cell Carcinoma - Dormant Projects (Contd..1), H1 2016 782
Renal Cell Carcinoma - Dormant Projects (Contd..2), H1 2016 783
Renal Cell Carcinoma - Dormant Projects (Contd..3), H1 2016 784
Renal Cell Carcinoma - Dormant Projects (Contd..4), H1 2016 785
Renal Cell Carcinoma - Dormant Projects (Contd..5), H1 2016 786
Renal Cell Carcinoma - Dormant Projects (Contd..6), H1 2016 787
Renal Cell Carcinoma - Dormant Projects (Contd..7), H1 2016 788
Renal Cell Carcinoma - Dormant Projects (Contd..8), H1 2016 789
Renal Cell Carcinoma - Dormant Projects (Contd..9), H1 2016 790
Renal Cell Carcinoma - Dormant Projects (Contd..10), H1 2016 791
Renal Cell Carcinoma - Dormant Projects (Contd..11), H1 2016 792
Renal Cell Carcinoma - Dormant Projects (Contd..12), H1 2016 793
Renal Cell Carcinoma - Dormant Projects (Contd..13), H1 2016 794
Renal Cell Carcinoma - Discontinued Products, H1 2016 795
Renal Cell Carcinoma - Discontinued Products (Contd..1), H1 2016 796
Renal Cell Carcinoma - Discontinued Products (Contd..2), H1 2016 797
Renal Cell Carcinoma - Discontinued Products (Contd..3), H1 2016 798
List of Figures
Number of Products under Development for Renal Cell Carcinoma, H1 2016 25
Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H1 2016 26
Number of Products under Development by Companies, H1 2016 27
Number of Products under Investigation by Universities/Institutes, H1 2016 35
Comparative Analysis by Late Stage Development, H1 2016 36
Comparative Analysis by Clinical Stage Development, H1 2016 37
Comparative Analysis by Early Stage Products, H1 2016 38
Assessment by Monotherapy Products, H1 2016 145
Assessment by Combination Products, H1 2016 146
Number of Products by Top 10 Targets, H1 2016 147
Number of Products by Stage and Top 10 Targets, H1 2016 147
Number of Products by Top 10 Mechanism of Actions, H1 2016 160
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 160
Number of Products by Top 10 Routes of Administration, H1 2016 169
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 169
Number of Products by Top 10 Molecule Types, H1 2016 171
Number of Products by Stage and Top 10 Molecule Types, H1 2016 171
